CD274 and neoplasm: The overall and cancer-specific survival analysis in patients with different tumor HLA-I and PD-L1 co-expression patterns (77 tumors analyzed) (HLA-I/PD-L1 double positive (23 tumors); HLA-I positive/PD-L1 negative (12 tumors) HLA-I negative/PD-L1 positive (17 tumors); and HLA-I/PD-L1 double negative (25 tumors), did not reveal any statistically significant differences between survival times in these groups (LogRank (Mantel-Cox) 7257; p = 0.064).